Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Clearmind Medicine Inc CMND

Healthcare
Clearmind Medicine Inc. is a psychedelic pharmaceutical biotech company. The Company is focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorders. The Company researches and develops psychedelic-based compounds and attempts to commercialize them as regulated medicines, foods, or... see more

Recent & Breaking News (NDAQ:CMND)

Clearmind Medicine Announces Pricing of US$2.25 Million Public Offering

GlobeNewswire September 14, 2023

Clearmind Medicine Announces Clinical Research Collaboration with Johns Hopkins University to Evaluate CMND-100 in Patients with Alcohol Use Disorder

GlobeNewswire September 6, 2023

The biotech/pharma team set up to enhance psychedelic therapeutics

Jonathon Brown August 14, 2023

Clearmind Medicine Announces Collaboration with CTS Ltd., a Leading Pharmaceutical and Consumer Products Company

GlobeNewswire August 14, 2023

SciSparc and Clearmind Collaboration Continues to Increase its Patent Portfolio in the Field of Movement Abnormalities in the U.S.

GlobeNewswire August 1, 2023

Clearmind Medicine Files Patent Application with USPTO for the Treatment of Dyskinesia; Further Strengthens its Already Robust IP Portfolio

GlobeNewswire August 1, 2023

Clearmind Medicine Announces Share-Based Payment for the Company's Consultants

GlobeNewswire July 17, 2023

Dr. Fatima Cody Stanford, Associate Professor of Medicine and Pediatrics at Harvard Medical School, Joins Clearmind Medicine's Scientific Advisory Board

GlobeNewswire July 11, 2023

Clearmind Medicine and SciSparc to Conduct Study Evaluating Combination Treatment for Obesity and Metabolic Syndrome

GlobeNewswire June 16, 2023

SciSparc and Clearmind Medicine to Conduct a Study Evaluating Their Combination Treatment for Obesity and Metabolic Syndrome

GlobeNewswire June 16, 2023

Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity

GlobeNewswire June 9, 2023

Clearmind Medicine Announces First US Site for its Phase I/IIa Clinical Trial Evaluating CMND-100 in Patients with Alcohol Use Disorder

GlobeNewswire May 22, 2023

Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price Notification

GlobeNewswire May 19, 2023

Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity

GlobeNewswire May 17, 2023

Clearmind (CSE:CMND) approved to conduct clinical trial on alcohol use disorder

Jonathon Brown May 12, 2023

Clearmind Medicine Announces IRB Approval to Conduct Clinical Trial on Alcohol Use Disorder

GlobeNewswire May 12, 2023

Clearmind Medicine Retains Crescendo Communications LLC. for Investor Relations and Announces Granting of Stock and Warrants

GlobeNewswire May 9, 2023

Clearmind Medicine Strengthens Scientific Advisory Board with Appointment of Prof. Joseph Tam

GlobeNewswire May 8, 2023

Clearmind (CSE:CMND) signs supply agreement for its upcoming clinical trial

Jonathon Brown May 2, 2023

Clearmind Medicine Announces Clinical Supply Agreement for its Upcoming Clinical Trial

GlobeNewswire May 2, 2023